Back to catalog
Bone research
Erdafitinib
30mL, 5mg/mL
Pan-FGFR tyrosine kinase inhibition research.
Overview
Erdafitinib is a potent fibroblast growth factor receptor (FGFR) inhibitor. It is extensively utilized in oncology and bone research to study FGFR-mediated signaling pathways.
Mechanism of action
It is a pan-FGFR inhibitor that competitively binds to the kinase domain to inhibit phosphorylation.
Dosage & concentration
5 mg/mL concentration. 30 mL bottle contains 150 mg total.
Storage & handling
Store in a cool, dark environment to preserve chemical integrity.
Research & studies
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.N Engl J Med · 2023
- Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.Lancet Oncol · 2023
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med · 2019